Moderna, Inc. has announced a strategic expansion of its U.S. manufacturing capabilities with the onshoring of drug product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts. The more than $140 million investment will enable the company to operate full end-to-end manufacturing for its mRNA medicines domestically, marking a significant milestone in strengthening America's biomanufacturing infrastructure.
Strategic Manufacturing Consolidation
The expansion represents the completion of Moderna's domestic manufacturing loop, bringing all production processes under one roof in the United States. "By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," said Stéphane Bancel, Chief Executive Officer of Moderna. "As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community."
This strategic move will support both commercial and clinical supply needs while reinforcing Moderna's commitment to domestic mRNA production. The company's decision reflects ongoing investment in U.S.-based infrastructure and builds upon its innovative mRNA platform that gained global recognition during its partnership with the U.S. Government through Operation Warp Speed.
Economic Impact and Timeline
The manufacturing expansion is expected to create several hundred highly skilled biomanufacturing jobs, providing a significant boost to the local Massachusetts economy. Construction at the Moderna Technology Center for the new drug product manufacturing capability has already commenced, with the company targeting completion by the first half of 2027.
Broader Platform Applications
Moderna's mRNA platform continues to drive potential biomedical breakthroughs across multiple therapeutic areas, including infectious diseases, cancer, rare diseases, and autoimmune disorders. The domestic manufacturing capability will support the company's pipeline of mRNA vaccines and therapeutics, ensuring robust supply chain resilience for future product development and commercialization.
The investment underscores Moderna's position as a pioneer and leader in mRNA medicine, with the technology platform enabling the development of treatments across diverse disease areas. The company's mission focuses on delivering the greatest possible impact to people through mRNA medicines, supported by this enhanced domestic manufacturing infrastructure.
